Cimetidine. Concomitant administration of 200 mg cimetidine QID did not alter the single dose pharmacokinetics of 30 mg meloxicam. Movalis nu trebuie administrat bolnavilor cu manifestări de astm, polipi nazali, angioedem sau urticarie ca urmare a administrării de acid acetilsalicilic sau alte AINS. Use in patients with fever and infection. The pharmacological activity of Movalis in reducing inflammation and possibly fever may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions. Fluid retention and oedema. Induction of sodium, potassium and water retention and interference with the natriuretic effects of diuretics may occur with NSAIDs. Cardiac failure or hypertension may be precipitated or exacerbated in susceptible patients as a result. For patients at risk, clinical monitoring is recommended. crestere a concentratiilor de potasiu (hiperkaliemie). Aceasta poate conduce la simptome cum ar fi:

Anticonceptionalele intra in categoria metodelor contraceptive si reprezinta forma farmaceutica a acestora ce sunt administrate sub forma de pilule sau tablete (comprimate) ori chiar si in forma de unguente sau creme. Patients at greatest risk of such a reaction are elderly individuals, dehydrated patients, those with congestive heart failure, liver cirrhosis, nephrotic syndrome and overt renal disease, those receiving concomitant treatment with a diuretic, ACE inhibitor or angiotensin II receptor antagonist or those having undergone major surgical procedures which led to hypovolaemia. In such patients, the renal function, including volume of diuresis, should be carefully monitored at the beginning of therapy. In rare cases, NSAIDs may cause interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome. The efficacy of meloxicam in treating the symptoms of osteoarthritis has been confirmed in several clinical studies. Two clinical studies of six months duration were performed in patients with osteoarthritis of the hip or knee. In the first study, the efficacy of meloxicam 15 mg (n = 306) and piroxicam 20 mg (n = 149) were found to be comparable, using as efficacy endpoints improvement in overall pain, pain on movement, global efficacy, change in duration of inactivity and change in quality of life score. In the second study, the efficacy of meloxicam 7.5 mg (n = 169) was found to be comparable to that of diclofenac 100 mg SR (n = 167) using similar endpoints.As with most NSAIDs, occasional increases in serum transaminase levels, increases in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen as well as other laboratory disturbances, have been reported. The majority of these instances involved transitory and slight abnormalities. Should any such abnormality prove significant or persistent, the administration of Movalis should be stopped and appropriate investigations undertaken. The use of Movalis tablets is contraindicated in patients with rare hereditary galactose intolerance, due to the lactose content of the formulations. GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.

Nefrotoxicitatea ciclosporinei poate fi crescută de AINS prin efecte mediate de prostaglandinele renale. Se va monitoriza funcţia renală pe parcursul tratamentului asociat. daca sunteti alergic (hipersensibil) la acid acetilsalicilic sau la alte medicamente antiinflamatoare nesteriodiene (AINS); Pre-existing asthma. Patients with asthma may have aspirin sensitive asthma. The use of aspirin in patients with aspirin sensitive asthma has been associated with severe bronchospasm which can be fatal. Since cross reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in such aspirin sensitive patients, Movalis should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with pre-existing asthma.

Deşi nu se cunosc date referitoare la Movalis, se ştie că AINS trec în laptele matern. De aceea, se recomandă evitarea administrării la femeile care alăptează.